Journalartikel
Autorenliste: Alidjanov, Jakhongir F.; Fritzenwanker, Moritz; Hoffman, Ivan; Wagenlehner, Florian M.
Jahr der Veröffentlichung: 2017
Seiten: 655-670
Zeitschrift: Future Microbiology
Bandnummer: 12
Heftnummer: 8
ISSN: 1746-0913
eISSN: 1746-0921
DOI Link: https://doi.org/10.2217/fmb-2016-0213
Verlag: Taylor and Francis Group
Abstract:
Ceftazidime-avibactam is a combination of a third-generation cephalosporin and a novel non-beta-lactam beta-lactamase inhibitor. This combination was recently recommended for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults with limited or no alternative treatment options. The current review is aimed to determine activity, efficacy and safety of ceftazidime-avibactam in the treatment of patients with complicated urinary tract infections.
Zitierstile
Harvard-Zitierstil: Alidjanov, J., Fritzenwanker, M., Hoffman, I. and Wagenlehner, F. (2017) Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections, Future Microbiology, 12(8), pp. 655-670. https://doi.org/10.2217/fmb-2016-0213
APA-Zitierstil: Alidjanov, J., Fritzenwanker, M., Hoffman, I., & Wagenlehner, F. (2017). Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. Future Microbiology. 12(8), 655-670. https://doi.org/10.2217/fmb-2016-0213
Schlagwörter
antimicrobial agents; avibactam; beta lactamase; beta-lactams; ceftazidime; ceftazidime drug combination; Gram-negative bacteria; INCLUDING ACUTE PYELONEPHRITIS; INHIBITOR COMBINATION; IN-VITRO ACTIVITY; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; NXL104 COMBINATIONS; SPECTRUM BETA-LACTAMASES; Urinary tract infections; US MEDICAL-CENTERS
